title: Does diabetes mellitus-induced bladder remodeling affect lower urinary tract function? ICI-RS 2011.
abstract: OBJECTIVE
  Due to an increase in aging population and changing eating habits diabetes mellitus (DM) type II is a rapidly increasing condition worldwide. Although not so detrimental as other co-morbidities, uropathy contributes to a significantly reduced quality-of-life in those affected. The purpose of this ICS-RS report is to highlight clinical and basic research data to outline directions for further research and possible treatment approaches.
  
  
  METHODS
  This report is based on a think tank presentation and discussion at the ICI-RS 2011, original research data and literature research.
  
  
  RESULTS
  Clinical and experimental data confirm that detrusor overactivity, both neurogenic and myogenic, and changes in transmitter regulation leading to a hyper- excitability of the detrusor are the major findings in diabetic neuropathic bladders. These findings seem to be related to an earlier stage of DM, whereas detrusor underactivity appears to be linked to later stages of DM. Detrusor smooth muscle cells seem to be modulated directly by hyperglycemia. Data support the theory that hyperglycemia-induced oxidative stress in the detrusor smooth muscle and that micro- and macrovascular events are also responsible for urologic complications of DM.
  
  
  CONCLUSIONS
  DM causes bladder remodelling leading to uropathy in a mulitfactorial way. Future research should focus on the effects of DM as a function of time and develop novel animal models looking at defined aspects as well as interaction of different aspects- such as oxidative stress in neurogenic, myogenic and urothelial components and the role of inflammation and hypoxia caused by vascular complications.
authors.affiliation: Department of Urology, Continence Clinic, Aachen University Clinic - RWTH, Aachen, Germany. rkirschner-hermanns@ukaachen.de
authors.forename: Ruth
authors.initials: R
authors.lastname: Kirschner-Hermanns
authors.forename: Firouz
authors.initials: F
authors.lastname: Daneshgari
authors.forename: Bahareh
authors.initials: B
authors.lastname: Vahabi
authors.forename: Lori
authors.initials: L
authors.lastname: Birder
authors.forename: Matthias
authors.initials: M
authors.lastname: Oelke
authors.forename: Samuel
authors.initials: S
authors.lastname: Chacko
mesh_terms: D000818:Animals; D048909:Diabetes Complications / Q000209:etiology* / Q000503:physiopathology; D003924:Diabetes Mellitus, Type 2 / Q000150:complications* / Q000503:physiopathology; D019317:Evidence-Based Medicine; D006801:Humans; D059411:Lower Urinary Tract Symptoms / Q000209:etiology* / Q000503:physiopathology; D009130:Muscle, Smooth / Q000294:innervation / Q000473:pathology / Q000503:physiopathology*; D018570:Risk Assessment; D012307:Risk Factors; D001743:Urinary Bladder / Q000294:innervation / Q000473:pathology / Q000503:physiopathology*; D001750:Urinary Bladder, Neurogenic / Q000209:etiology / Q000503:physiopathology; D053201:Urinary Bladder, Overactive / Q000209:etiology / Q000503:physiopathology